Ratio Therapeutics Appoints Dr. Marcel Reichen As Chief Strategy Officer To Drive Global Growth In Radiopharmaceuticals

Ratio Therapeutics Inc., a Boston-based pharmaceutical company developing advanced radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Dr. Marcel Reichen as its Chief Strategy Officer. Dr. Reichen brings over ten years of global experience in the pharmaceutical and radioligand therapy (RLT) sectors, known for his success in driving strategic growth and value creation.

Dr. Jack Hoppin, Chairman and CEO of Ratio Therapeutics, emphasized that this appointment comes at a pivotal stage as the company expands its partnerships and strengthens its radiopharmaceutical pipeline. He noted that Dr. Reichen’s expertise in RLT strategy and international business development will play a key role in shaping Ratio’s future growth and enhancing its leadership in precision oncology.

Expressing his enthusiasm for the new role, Dr. Reichen shared his commitment to advancing Ratio’s innovative approach to targeted radiopharmaceuticals. He previously held leadership positions at Novartis and Advanced Accelerator Applications, where he guided strategic initiatives and evaluated opportunities in the radioligand therapy field. Earlier in his career, he was part of Bayer Business Consulting, advising on R&D productivity and digital transformation. Dr. Reichen holds a Ph.D. in Biochemical Engineering from University College London, an M.Sc. in Mechanical Engineering from ETH Zurich, and an MBA from the University of St. Gallen.